D.4 Safety and efficacy of delandistrogene moxeparvovec versus placebo in Duchenne muscular dystrophy (EMBARK): Pivotal Phase 3 primary results.
Saved in:
| Title: | D.4 Safety and efficacy of delandistrogene moxeparvovec versus placebo in Duchenne muscular dystrophy (EMBARK): Pivotal Phase 3 primary results. |
|---|---|
| Authors: | Mendell, JR, Muntoni, F, McDonald, CM, Mercuri, EM, Ciafaloni, E, Komaki, H, Leon-Astudillo, C, Nascimento, A, Proud, C, Schara-Schmidt, U, Veerapandiyan, A, Zaidman, CM, Guridi, M, Murphy, AP, Reid, C, Wandel, C, Darton, E, Mason, S, Potter, RA, Singh, T, et al |
| Source: | The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2024 Supplement; Vol. 51. |
| Journal Info: | Publisher: Cambridge University Press ISSN: 0317-1671 |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
